<code id='9F892920EC'></code><style id='9F892920EC'></style>
    • <acronym id='9F892920EC'></acronym>
      <center id='9F892920EC'><center id='9F892920EC'><tfoot id='9F892920EC'></tfoot></center><abbr id='9F892920EC'><dir id='9F892920EC'><tfoot id='9F892920EC'></tfoot><noframes id='9F892920EC'>

    • <optgroup id='9F892920EC'><strike id='9F892920EC'><sup id='9F892920EC'></sup></strike><code id='9F892920EC'></code></optgroup>
        1. <b id='9F892920EC'><label id='9F892920EC'><select id='9F892920EC'><dt id='9F892920EC'><span id='9F892920EC'></span></dt></select></label></b><u id='9F892920EC'></u>
          <i id='9F892920EC'><strike id='9F892920EC'><tt id='9F892920EC'><pre id='9F892920EC'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:fashion    - browse:9
          The New York Stock Exchange's screen displays a logo of Johnson & Johnson — pharma coverage from STAT
          AP/Richard Drew

          Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development. 

          The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry. 

          advertisement

          Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot